These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 23911536

  • 1. Apolipoprotein-defined and NMR lipoprotein subclasses in the veterans affairs diabetes trial.
    Azar M, Lyons TJ, Alaupovic P, Stoner JA, Quiroga C, Kaufman DG, Lopes-Virella M, Klein RL, Jenkins AJ, VADT Study Group.
    J Diabetes Complications; 2013; 27(6):627-32. PubMed ID: 23911536
    [Abstract] [Full Text] [Related]

  • 2. The effect of intensive glucose lowering on lipoprotein particle profiles and inflammatory markers in the Veterans Affairs Diabetes Trial (VADT).
    Koska J, Saremi A, Bahn G, Yamashita S, Reaven PD, Veterans Affairs Diabetes Trial Investigators.
    Diabetes Care; 2013 Aug; 36(8):2408-14. PubMed ID: 23536583
    [Abstract] [Full Text] [Related]

  • 3. Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus.
    Shimabukuro M, Higa M, Tanaka H, Shimabukuro T, Yamakawa K, Masuzaki H.
    Diabet Med; 2011 Jul; 28(7):856-64. PubMed ID: 21244474
    [Abstract] [Full Text] [Related]

  • 4. Effects of marine n-3 fatty acid supplementation on lipoprotein subclasses measured by nuclear magnetic resonance in subjects with type II diabetes.
    Mostad IL, Bjerve KS, Lydersen S, Grill V.
    Eur J Clin Nutr; 2008 Mar; 62(3):419-29. PubMed ID: 17327864
    [Abstract] [Full Text] [Related]

  • 5. Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: associations with lipoprotein subclasses.
    Klein RL, McHenry MB, Lok KH, Hunter SJ, Le NA, Jenkins AJ, Zheng D, Semler AJ, Brown WV, Lyons TJ, Garvey WT, DCCT/EDIC Research Group.
    Metabolism; 2004 Oct; 53(10):1296-304. PubMed ID: 15375785
    [Abstract] [Full Text] [Related]

  • 6. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial.
    Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, McNamara JR, Bloomfield HE, Robins SJ.
    Circulation; 2006 Mar 28; 113(12):1556-63. PubMed ID: 16534013
    [Abstract] [Full Text] [Related]

  • 7. Associations between intensive diabetes therapy and NMR-determined lipoprotein subclass profiles in type 1 diabetes.
    Zhang Y, Jenkins AJ, Basu A, Stoner JA, Lopes-Virella MF, Klein RL, DCCT/EDIC Research Group, Lyons TJ.
    J Lipid Res; 2016 Feb 28; 57(2):310-7. PubMed ID: 26658239
    [Abstract] [Full Text] [Related]

  • 8. Lipoprotein subclass profiles in individuals with varying degrees of glucose tolerance: a population-based study of 9399 Finnish men.
    Wang J, Stančáková A, Soininen P, Kangas AJ, Paananen J, Kuusisto J, Ala-Korpela M, Laakso M.
    J Intern Med; 2012 Dec 28; 272(6):562-72. PubMed ID: 22650159
    [Abstract] [Full Text] [Related]

  • 9. NMR-determined lipoprotein subclass profile predicts type 2 diabetes.
    Hodge AM, Jenkins AJ, English DR, O'Dea K, Giles GG.
    Diabetes Res Clin Pract; 2009 Jan 28; 83(1):132-9. PubMed ID: 19091436
    [Abstract] [Full Text] [Related]

  • 10. Apolipoprotein-defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort.
    Jenkins AJ, Yu J, Alaupovic P, Basu A, Klein RL, Lopes-Virella M, Baker NL, Hunt KJ, Lackland DT, Garvey WT, Lyons TJ, DCCT/EDIC Research Group.
    J Diabetes Complications; 2013 Jan 28; 27(5):447-53. PubMed ID: 23850262
    [Abstract] [Full Text] [Related]

  • 11. Effects of glyburide treatment on serum lipoprotein and apolipoprotein concentrations and ratios in non-insulin-dependent diabetes mellitus.
    Waysbort J, Regitz G, Brunner D.
    Clin Ther; 1988 Jan 28; 10(4):392-400. PubMed ID: 3152618
    [Abstract] [Full Text] [Related]

  • 12. Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study.
    Goff DC, D'Agostino RB, Haffner SM, Otvos JD.
    Metabolism; 2005 Feb 28; 54(2):264-70. PubMed ID: 15690322
    [Abstract] [Full Text] [Related]

  • 13. Hormone therapy, lipoprotein subclasses, and coronary calcification: the Healthy Women Study.
    Mackey RH, Kuller LH, Sutton-Tyrrell K, Evans RW, Holubkov R, Matthews KA.
    Arch Intern Med; 2005 Mar 14; 165(5):510-5. PubMed ID: 15767525
    [Abstract] [Full Text] [Related]

  • 14. Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: a randomized crossover study.
    Chan SY, Mancini GB, Ignaszewski A, Frohlich J.
    BMC Clin Pharmacol; 2008 Oct 28; 8():10. PubMed ID: 18957124
    [Abstract] [Full Text] [Related]

  • 15. Fenofibrate and rosiglitazone improve quality of lipoproteins in patients with type 2 diabetes mellitus.
    Vrablík M, Dobiásová M, Stulc T, Kasalová Z, Dolezalová R, Prázný M, Fait T, Ceska R.
    Neuro Endocrinol Lett; 2008 Feb 28; 29(1):146-50. PubMed ID: 18283261
    [Abstract] [Full Text] [Related]

  • 16. Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy.
    Habib SS, Aslam M, Naveed AK, Razi MS.
    Saudi Med J; 2006 Feb 28; 27(2):174-80. PubMed ID: 16501671
    [Abstract] [Full Text] [Related]

  • 17. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study.
    Festa A, Williams K, Hanley AJ, Otvos JD, Goff DC, Wagenknecht LE, Haffner SM.
    Circulation; 2005 Jun 28; 111(25):3465-72. PubMed ID: 15983261
    [Abstract] [Full Text] [Related]

  • 18. Study comparing the effect of pioglitazone in combination with either metformin or sulphonylureas on lipid profile and glycaemic control in patients with type 2 diabetes (ECLA).
    Karamanos B, Thanopoulou A, Drossinos V, Charalampidou E, Sourmeli S, Archimandritis A, Hellenic ECLA Study Group.
    Curr Med Res Opin; 2011 Feb 28; 27(2):303-13. PubMed ID: 21142615
    [Abstract] [Full Text] [Related]

  • 19. Effects of glibenclamide on serum lipids, lipoproteins, thromboxane, beta-thromboglobulin, and prostacyclin in non-insulin-dependent diabetes mellitus.
    Waysbort J, Regitz G, Chaimowitz D, Tuval M, Nakash I, Brunner D.
    Clin Ther; 1988 Feb 28; 10(4):358-71. PubMed ID: 2978874
    [Abstract] [Full Text] [Related]

  • 20. Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes.
    Peters Harmel AL, Kendall DM, Buse JB, Boyle PJ, Marchetti A, Lau H.
    Curr Med Res Opin; 2004 Feb 28; 20(2):215-23. PubMed ID: 15006017
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.